Several routine reference methods were used: cobas® KRAS Mutation Test (Roche; n = 119), Ion Torrent AmpliSeqTM Colon and Lung Cancer Research Panel (Life Technologies, n = 52), therascreen® KRAS Pyro Kit (Qiagen, n = 85), therascreen® RAS Extension Pyro Kit (Qiagen, n = 57), HRM screening (combined with the previous 2 therascreen® kits, n = 34), HRM screening and pyrosequencing (n = 32), HRM screening and Sanger (n = 34), Sanger sequencing (as only method n = 59). The gene discussed is KRAS; the disease is lung cancer.